The Effects of Glucomannan on Weight Loss

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Denise Holtzman MS DC, New York Chiropractic College
ClinicalTrials.gov Identifier:
NCT01709955
First received: October 16, 2012
Last updated: October 17, 2012
Last verified: October 2012
  Purpose

The purpose of this study is to determine if the herb, Glucomannan, is an effective non-pharmacological appetite suppressant for overweight or Class I obese patients. The study design will not include any other lifestyle changes which enhance weight loss in order to completely isolate the effects of Glucomannan as a non-pharmacological appetite suppressant.


Condition Intervention Phase
Obesity
Dietary Supplement: Glucomannan
Other: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by New York Chiropractic College:

Primary Outcome Measures:
  • Weight Loss [ Time Frame: 30 Days ] [ Designated as safety issue: No ]

Enrollment: 43
Study Start Date: February 2011
Study Completion Date: July 2011
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Gucomannan Dietary Supplement: Glucomannan
750 MG of Glucomannan in capsule form
Placebo Comparator: Placebo pill Other: Placebo
750 mg of Cellulose powder in a capsule form

  Eligibility

Ages Eligible for Study:   21 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:Subjects will be recruited based upon the category of them wanting to lose 50 pounds.

Subjects must be able to swallow the capsule whole with water.

Exclusion Criteria:

  1. Self-reported use of prescription medication other than hormonal birth control (such as medication for diabetes, hypertension hypothyroidism, heart disease, cancer, etc.)
  2. Pregnancy
  3. Age younger than 21 or older than 60 years of age.
  4. Screening for hypertension during the first laboratory visit that reveals a systole greater than 120 and a diastole greater than 90.
  5. BMI calculations based upon height and weight measurements at the first laboratory visit that reveal a BMI less than 25 or greater than 35.
  6. Self-reported iron-deficiency anemia, osteoporosis, and hypoglycemia.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Denise Holtzman MS DC, Associate professor, New York Chiropractic College
ClinicalTrials.gov Identifier: NCT01709955     History of Changes
Other Study ID Numbers: 10-13
Study First Received: October 16, 2012
Last Updated: October 17, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by New York Chiropractic College:
Obesity
Overweight
Glucomannan

Additional relevant MeSH terms:
Obesity
Overnutrition
Nutrition Disorders
Overweight
Body Weight
Signs and Symptoms
(1-6)-alpha-glucomannan
Cathartics
Gastrointestinal Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on October 16, 2014